<DOC>
	<DOCNO>NCT01074333</DOCNO>
	<brief_summary>This observational , non-interventional , uncontrolled , multicentric safety study subject epidermal growth factor receptor ( EGFR ) -expressing , V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog ( KRAS ) wild-type mCRC . The study aim collect safety data related Erbitux treatment total least 400 mCRC subject 35 institution start treatment Erbitux progressive disease , Erbitux-related intolerable toxicity , death , withdrawal Erbitux treatment ( whichever occurs first ) .</brief_summary>
	<brief_title>An Observational Study ErbituxÂ® Patients With Metastatic Colorectal Cancer ( mCRC ) Refractory Irinotecan-containing Treatment</brief_title>
	<detailed_description>Colorectal cancer fourth common form cancer worldwide remain leading malignancy incidence mortality . Erbitux immunoglobulin G1 monoclonal antibody specifically block ligand bind EGFR high affinity , thereby prevent downstream signal transduction cellular response . Erbitux enhance effect common chemotherapy agent radiotherapy demonstrate minimal overlap toxicity approach . Erbitux combination treatment modality , also show efficacy treatment number solid tumor , include mCRC , squamous cell carcinoma head neck , non-small cell lung cancer . Based several study conduct past , Erbitux approve treatment subject EGFR-expressing , KRAS wild-type mCRC , single agent subject fail oxaliplatin-and irinotecan-based therapy intolerant irinotecan combination chemotherapy . The common Erbitux-related adverse event ( AEs ) relate skin , infusion , hypersensitivity reaction . Other side effect Erbitux monotherapy include asthenia , dyspnoea , mucositis , nausea , pain , fever headache . OBJECTIVES Primary objective : - To obtain safety information use Erbitux subject EGFR-expressing , KRAS wild-type mCRC term frequency severity AEs Secondary objective : - To gather clinical efficacy information treatment The study primarily collect safety data related Erbitux treatment along clinical efficacy information start treatment Erbitux progressive disease , Erbitux relate intolerable toxicity , death , withdrawal Erbitux treatment whichever occur first . All subject enrol order visit physician making contract subject observe period 4 month average . Erbitux prescribed mCRC subject accord approve national label routine clinical practice supervision investigator experience use antineoplastic medicinal product . Prior first infusion , subject receive pre-medication antihistamine corticosteroid . The initial dose Erbitux 400 mg/m2 body surface area subsequent weekly dos 250 mg/m2 administer intravenously ( i.v . ) via in-line filtration infusion pump , gravity drip , syringe pump . The recommended infusion period initial dose 120 minute subsequent weekly dos 60 minute maximum infusion rate exceed 5 ml/min . The observational period study define first infusion Erbitux 28 day last infusion Erbitux subject , regardless reason discontinuation Erbitux treatment .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Subjects eligible Erbitux treatment accord indication national label Erbitux ( i.e . EGFR express , KRAS wildtype metastatic colorectal adenocarcinoma ) . Subjects fail oxaliplatin irinotecanbased therapy intolerant irinotecan mCRC . Subjects sign informed consent form Subjects fall approve indication accord national label Erbitux .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Metastasis</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Erbitux</keyword>
	<keyword>Epidermal growth factor receptor</keyword>
</DOC>